Regencell Bioscience Holdings Ltd (RGC) Form 6-K — May 22, 2026

Regencell Bioscience Holdings Limited (Nasdaq: RGC) announced the closing of a registered direct offering of ordinary shares, raising approximately $20.0 million in gross proceeds. The offering consisted of 985,222 ordinary shares sold at a price of $20.30 per share. The deal was led by a $19 million investment from a new fundamental institutional investor, with additional participation from Univest Securities, LLC, which acted as the sole placement agent. The offering was conducted pursuant to a shelf registration statement on Form F-3 that became effective on March 30, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.